Skip to main content

Two join to work on skincare

Kao has signed an agreement with its Japanese compatriot Daiichi Sankyo Healthcare, a specialist in over-the-counter (OTC) drugs, to collaborate in joint development in skin care, using each other's skin- and health-related fundamental and formulation technologies. Daiichi Sankyo Healthcare will use Kao's skin product formulation technology to develop OTC drugs.

Feature article - CPHI Frankfurt: Strong markets, multiple modalities

Pharmaceutical CDMOs are continuing to invest in a buoyant market. We report from CPHI Frankfurt

The mood among CDMOs remained buoyant at the rebranded CPHI Frankfurt show, which took place on 1-3 November. There were several announcements of major investments and most of the exhibitors SCM spoke to were optimistic about continued rapid growth, particularly in new modalities of all kinds.

Ampac claims revolution in continuous processing

Following launch at a symposium in Boston in September, Ampac Fine Chemicals (AFC), an SK Pharmteco company, has announced the development of a new series of skid-based modules for continuous flow processes. These, it claims, will revolutionise the technique, closing the gap between benchtop development with microreactors and manufacturing scale.

New owner for Alcami

Global Healthcare Opportunities, a European specialist investor in global healthcare, and The Vistria Group, a middle-market private investment firm, have agreed to acquire US-based CDMO Alcami from Madison Dearborn Partners and Ampersand Capital Partners. They will each have 50% stakes.

Feature article - Biologics outsourcing to surge in 2023 as China’s innovation engine stalls

Vicky Xia and Joel Ranck of BioPlan share some first insights from the CPHI Annual Report

Having already benefitted from a COVID-based boom in the last two years, outsourcing of biologics globally is set to continue growing significantly in 2023. No production cliff is expected, even as COVID-related contracts reduce in scale, but the rapid growth of China’s biologics sector will slow.

Cambrex expands at two US sites

Cambrex has announced it is investing in a new facility in Minneapolis. It will operate as an extension of the flagship facility in Charles City, Iowa (pictured), which is simultaneously seeing further expansion.

The new site, near Minneapolis–St. Paul Airport, will specialise in analytical and chemical development for small molecule drug candidates and will cover 1,950 m2 R&D. This will double Cambrex’s analytical and chemical development footprint in the Midwest, according to CEO Thomas Loewald, while creating 46 jobs.

Expanding the chiral pool

A team led by Mark Walsh and Matthew Kitching from Durham University has published an article in JACS Au, detailing how they found nearly 1,800 conglomerate crystal structures within the Cambridge Structural Database (CSD). These are molecules that are synthesised by racemic methods but which show spontaneously enriched chirality upon crystallisation.

Subscribe to Pharmaceuticals